Reynoso Jamie L. sold $11K of CLOV
Reynoso Jamie L. (CEO, Medicare Advantage) sold 2,384 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.68 on 2026-07-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction is primarily a disclosure of insider activity. Without new company fundamentals, it is more likely to influence short-term sentiment than to change valuation drivers.
Market read
Traders may note the insider sale for sentiment, but it is unlikely to be a standalone catalyst.
What to watch
The filing does not disclose any new company-specific catalyst (earnings, guidance, trials, contracts), so traders should avoid over-weighting it versus upcoming fundamentals.
Background
This is an SEC Form 4 reporting an officer’s open-market sale of CLOV shares, with a stated pre-arranged Rule 10b5-1 plan.
Ticker impact
Clover Health CEO Jamie L. Reynoso sold 2,384 shares on 2026-07-08 at $4.6800, totaling $11,157.12, under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.
The filing is a Form 4 insider open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying new operational or guidance information.
Market effects
Minimal read-through to the Medicare Advantage/healthcare services sector because this is a small, planned insider transaction.
None.
None.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish fundamentals.
Key entities
- issuerClover Health Investments, Corp. /DE
Subject of the Form 4 insider transaction disclosure.
- insiderReynoso Jamie L.
CEO, Medicare Advantage, who executed the open-market sale under a 10b5-1 plan.
